In recent years, important steps have been taken to improve the treatment of congenital adrenal hyperplasia (CAH), a relatively stagnant area for decades. In this review, we summarize these advances and propose future lines of investigation.
INTRODUCTION
Congenital adrenal hyperplasia (CAH) comprises a group of autosomal recessive enzymatic defects of cortisol synthesis. Over 90% of CAH cases are attributed to 21-hydroxylase (CYP21A2) deficiency (21OHD), one of the most common genetic diseases [1] . The defective cortisol production prompts the hypothalamus and hypophysis to augment the release of corticotropin releasing hormone (CRH) and adrenocorticotropin (ACTH), respectively. In the face of a defective CYP21A2, the upstream steroid precursors such as 17-hydroxyprogesterone (17OHP), are directed toward formation of androgens ( Fig. 1 ). The CYP21A2 defects range from complete to mild, rendering classic forms of 21OHD, in which the cortisol and sometimes mineralocorticoid production is compromised, and nonclassic 21OHD, in which increased ACTH secretion allows compensation to maintain normal cortisol synthesis. The adrenal androgen excess is, at least roughly, inversely correlated with the cortisol production. Girls with classic 21OHD are born with masculinized external genitalia, often managed with corrective surgery. Patients with nonclassic 21OHD might suffer from hirsutism, acne, irregular menses, premature pubarche, rapid somatic growth, advanced bone age, and subfertility [2] [3] [4] [5] ; however, most nonclassic 21OHD patients never receive this diagnosis.
Glucocorticoid therapy did not become available until the 1950s, almost a century after the first description of the disease. Although these drugs have prolonged survival routinely into adulthood, CAH treatment has remained relatively stagnant since then and has failed to meet all of the complex clinical needs of these patients. Unlike other forms of adrenal insufficiency, treatment of 21OHD aims not only to replace the deficient hormones but also to blunt the ACTH secretion, the major driver of the adrenal androgen production. Current guidelines for CAH treatment are flexible but emphasize the importance of minimizing potential iatrogenic Cushing syndrome [6] . Adequate adrenal androgen suppression, however, is often difficult to achieve without supraphysiologic doses of glucocorticoids and their associated detrimental effects. Alternative, nonglucocorticoid treatment strategies to target the adrenal androgen excess have only recently begun to emerge. Figure 2 depicts potential therapeutic approaches to manage the adrenal androgen excess in CAH. Such strategies include: interference with the synthesis or function of CRH, ACTH, or key androgenic enzymes; nonselective adrenal steroidogenesis blockade; and androgen receptor antagonists. In the recent years, investigators have strived to improve CAH treatment by optimizing the glucocorticoid delivery systems, as well as by
KEY POINTS
The goals of CAH treatment are to achieve adequate androgen suppression without inducing iatrogenic Cushing syndrome and associated comorbidities.
Glucocorticoid replacement can be optimized by preparations that replicate the physiologic secretion pattern, such as modified-release oral hydrocortisone and continuous subcutaneous delivery devices.
Nonglucocorticoid strategies to address the excessive androgen production in CAH include drugs that inhibit key androgen biosynthetic enzymes (CYP17A1 inhibitors) or ACTH secretion (corticotropin-releasing hormone receptor type 1 antagonists).
Long-term clinical studies of recently developed treatments and exploration of novel therapeutic strategies in both children and adults with CAH are essential to determine optimal management for the future. 
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GLUCOCORTICOID TREATMENT
Glucocorticoids, with or without mineralocorticoids and sodium supplementation, have constituted the cornerstone of 21OHD management at all ages. All glucocorticoid drugs substitute the deficient endogenous cortisol synthesis in classic 21OHD and partially restore the negative feedback to the hypothalamus and the pituitary, to dampen their exaggerated secretion of CRH and ACTH, respectively, thus decreasing adrenal androgen synthesis. Although exogenous glucocorticoids satisfactorily substitute for the cortisol deficiency in most patients, sufficient suppression of ACTH, particularly early in the morning, has been challenging with the currently available formulations. Under physiologic conditions, ACTH is secreted with a circadian rhythmicity, typically rising about 03:00 h in early morning, reaching a peak by 06:00-08:00 h and declining to nadir in the evening [7, 8] . Oral glucocorticoids regimens aim to roughly mimic this diurnal pattern but allow the ACTH suppression to escape in-between doses [9] . The effects on ACTH secretion vary widely with the different types of glucocorticoids and their frequency of administration. Traditional substitution regimens include hydrocortisone, administered two or three times daily, the intermediate-acting prednisone or prednisolone, or the long-acting dexamethasone. Hydrocortisone is usually preferred in children, and the lowest possible doses are used to avoid growth suppression [10] . In adults, the intermediate and long-acting synthetic glucocorticoids are often preferred, because of a more convenient dosing schedule, although with a higher risk of unfavorable effects, such as obesity, dermal atrophy, insulin resistance, hypertension, and bone loss [11] [12] [13] [14] [15] [16] . In the recent years, investigators have worked on developing new glucocorticoid delivery systems, which could better replicate the physiologic circadian rhythm. A dual-release hydrocortisone, consisting of an extended-release core surrounded by an immediate-release coating, was initially developed for once-daily first morning administration in patients with primary adrenal insufficiency (Plenadren; ViroPharma, Maidenhead, United Kingdom) [17] . This dual-release hydrocortisone at 30 mg/day achieved improved body weight, glucose metabolism, and both systolic blood pressure and diastolic blood pressure, compared with the similar total daily hydrocortisone, administered in three divided doses, after 3 months of treatment [18] . This pharmacologic strategy, however, does not provide any early morning cortisol rise and, thus, is not designed to suppress the ACTH and the adrenal androgens during this window. Although small trials of this product have been conducted in CAH patients, no studies have been published at the time of this writing. Another oral modified-release multiparticulate hydrocortisone, Chronocort (Diurnal, UK), was formulated to reproduce the physiologic early morning rise in cortisol when administered at bedtime [19] . In a phase 2, open-label, crossover study of 14 patients (7 men, ages 17-55) with classic 21OHD, 30 mg Chronocort administered at 22:00 h, led to a single cortisol peak approximately 8 h later, leading to significantly lower 08:00 h 17OHP compared with conventional hydrocortisone administered three times daily [20] . When Chronocort was administered as a single bedtime dose, however, the average 17OHP, androstenedione, and ACTH over 24 h were not suppressed as well during conventional hydrocortisone replacement. More recently, a phase 2, open-label trial of 16 adults (eight women) with classic CAH studied a reformulated Chronocort product administered twice daily, initially 10 mg at 07:00 h and 20 mg at 23:00 h, and titrated over 6 months based on androstenedione, 17OHP, and clinical symptomatology [21 && ]. Serum steroids and other clinical parameters were compared for each patient on their various glucocorticoid replacement regimens prescribed prior to entering this study. Compared with conventional therapy, this Chronocort regimen resulted in lower 24 h (P ¼ 0.003), morning (07:00-15:00 h; P ¼ 0.0008) and afternoon (15:00-23:00 h; P ¼ 0.009) area under the curve (AUC) for androstenedione and lower 24 h (P ¼ 0.021) and morning (07:00-15:00 h; P ¼ 0.018) AUC for 17OHP, despite a lower hydrocortisone dose equivalent (28 AE 11.8 vs 25.9 AE 7.1 mg/d).
Along with the lower glucocorticoid exposure, patients also experienced an increase in lean body mass, morning HOMA-IR, and osteocalcin. Interestingly, the bone mineral density declined slightly but significantly during Chronocort treatment in women, a change attributed to the improved androgen control. Long-term studies of more patients, including children, would help clarify the effects of such modified-release glucocorticoid preparations on various metabolic parameters and on clinically relevant outcomes, such as cardiovascular and fracture risks.
PARENTERAL GLUCOCORTICOIDS
A more precise titration of glucocorticoid delivery can be attained with parenteral administration, although this approach has practical limitations. A small study conducted a decade ago showed that intravenous administration of hydrocortisone in a pattern similar to physiologic cortisol secretion brings ACTH and 17OHP much closer to normal than conventional therapy, in both adrenal insufficiency and CAH patients [22] . In 2009, hydrocortisone continuously administered via a subcutaneous insulin pump was reported for the first time in a CAH patient, a 14.5-year-old boy with poor bioavailability and increased clearance of oral hydrocortisone [23] . This patient achieved better control on a lower total daily dose of hydrocortisone with subcutaneous vs oral hydrocortisone, which allowed normal pubertal progression over several years.
More recently, continuous subcutaneous hydrocortisone infusion was found to be superior to conventional oral delivery in a prospective crossover, randomized, multicenter clinical trial of 33 patients with Addison disease [24 & ]. The subcutaneous infusion was adjusted based on salivary cortisol levels (obtained between 06:00-08:00 and 11:00-12:00 h) and morning serum cortisol after 3-5 days, to achieve a morning salivary cortisol in the middle to upper reference range, an evening salivary cortisol in the lower reference range, and a normal morning serum cortisol. During the 3 months of treatment, patients on continuous subcutaneous hydrocortisone infusion had significantly lower mean ACTH concentrations, and their morning serum and 24 h salivary cortisol profiles were closer to physiologic patterns, with improved quality of life metrics compared with the conventional oral hydrocortisone treatment. Nevertheless, a doubleblind placebo-controlled trial did not show any improvement with continuous subcutaneous hydrocortisone infusion in subjective health status in patients with Addison disease and good baseline health status [25] .
Another group attempted to further improve the dynamics of hydrocortisone administration by using a portable pulsatile continuous subcutaneous delivery system along with real-time sampling of ACTH and cortisol [26 & ]. This paradigm was achieved through an automated blood sampling system connected to a venous cannula inserted in the antecubital fossa, through which cortisol and ACTH were sampled every 10 and 60 min, respectively. The study was conducted in healthy volunteers in whom the intrinsic adrenal function was suppressed with dexamethasone or metyrapone. Using this system, physiological circadian and ultradian rhythmicity was replicated. Although these concepts are promising, future studies in patients with CAH are important for determining the patterns of glucocorticoid administration necessary not only in physiologic circumstances, but also to adequately suppress ACTH and androgen synthesis.
The widespread implementation of parenteral hydrocortisone for CAH patients faces several hurdles. Similar to the use of insulin pumps in diabetic patients, these devices involve uninterrupted equipment wear, high cost, considerable patient sophistication, and the potential for local irritation and malfunction, which is particularly risky in patients with complete glucocorticoid deficiency. In addition, the commercial hydrocortisone formulations (hydrocortisone semisuccinate, Solu-cortef, Pfizer) are not designed for subcutaneous administration, and frequent infusion site reactions have been anecdotally reported, possibly because of the preservatives or other components of the preparation.
NONGLUCOCORTICOID TREATMENT
A radical approach intended to eradicate the adrenal androgen excess is surgical removal of the adrenal glands. Although surgery often achieves this objective in the short term [27] , bilateral adrenalectomy leaves patients fully dependent on exogenous glucocorticoid replacement and puts them at risk for adrenal crises [28, 29] , which can be fatal. Patients and parents should never be counseled that adrenalectomy will permanently cure the hyperandrogenemia, because of the development of adrenal rest tumors in the testes [29] in men or in the ovaries [30] and retroperitoneum [31] in women. In one study, hyperandrogenemia recurred in eight of 18 patients following adrenalectomy [29] . Other complications following adrenalectomy include hyperpigmentation and pituitary corticotrope adenoma formation requiring more surgery [32] . For these reasons, the initial enthusiasm from short-term results has given way to a more tempered long-term view, and bilateral adrenalectomy has fallen out of favor in the past 2 decades.
CHEMICAL ADRENALECTOMY
Chemical adrenalectomy with mitotane was used as a measure of last resort after failure of supraphysiologic doses of glucocorticoids in a 29-year-old man with classic 21OHD and testicular adrenal rest tumors, causing azoospermia and infertility [33] . During 2 years of treatment with mitotane, serum 17OHP and androstenedione, as well as TART volume, decreased substantially despite a further increase in ACTH. Conversely, pituitary gonadotropins, inhibin B and sperm count increased significantly, leading to a successful in-vitro fertilization. Side-effects of mitotane include anorexia and nausea, fatigue and depression, confusion and ataxia [34] , and increased hydrocortisone requirement because of the profound induction of CYP3A4 enzyme and enhanced cortisol metabolism [35] . This patient experienced hyponatremia and weight loss, probably because of reduced cortisol exposure, which resolved with higher doses of hydrocortisone and fludrocortisone. Recent studies suggest that the adrenolytic effect of mitotane is due to its inhibition of sterol-O-acyltransferase (also known as acyl-coenzyme A: cholesterol acyltransferase or ACAT1), which increases free cholesterol and oxysterols, and subsequently induces an endoplasmic reticulum stress response in NCI-H295 cells [36] .
ANDROGEN BIOSYNTHESIS INHIBITORS
With the current formulations available, physiologic glucocorticoid doses are not sufficient to normalize CRH and ACTH production, resulting in sustained androgen excess despite adequate cortisol replacement. Thus, alternative therapies that obviate the need for supraphysiologic exogenous glucocorticoids are highly desirable for all CAH patients. One potential strategy is to inhibit key enzymes of androgen biosynthesis (Fig. 2) such as 17a-hydroxylase/17,20-lyase (CYP17A1, P450c17). Abiraterone is a potent inhibitor of CYP17A1 [37] , an enzyme required for the synthesis of all androgens. Abiraterone acetate, the oral prodrug of abiraterone, profoundly decreases serum testosterone and improves survival in men with castration-resistant prostate cancer [38] [39] [40] . In a recent phase I open-label, multiple-dose clinical study, abiraterone acetate was administered for 6 days to adult women with classic 21OHD and elevated androgen production, while receiving physiological hydrocortisone doses of approximately 20 mg/day [41 && ]. All six participants enrolled had serum androstenedione concentrations more than 1.5 times above the upper limit of normal (>345 ng/ dl or >12 nmol/l). Abiraterone acetate at 100 mg/ day decreased the mean predose androstenedione on day 6 from 764 to 254 ng/dl and further decreased androstendione during the 8 h after the final dose. At 250 mg/day, abiraterone acetate normalized the androstenedione 24 h after the final dose in all six participants. Serum testosterone and urinary metabolites (androsterone and etiocholanolone glucuronides) declined in parallel with androstenedione, and the response correlated well with the abiraterone acetate exposure. Because the 17-hydroxylase activity of CYP17A1 is needed for cortisol synthesis, blockade with abiraterone acetate in patients with normal adrenal function causes a marked increase of 11-deoxycorticosterone ( Fig. 1) , leading to hypertension and hypokalemia unless a glucocorticoid, such as prednisolone, is coadministered [42] . In 21OHD, however, the inherited enzymatic defect prevents 11-deoxycorticosterone accumulation and the ensuing side-effects, as was demonstrated in this study. Although no serious side-effects were observed in this short-term phase I clinical trial, one concern is the potential for adrenal rest expansion if ACTH is allowed to remain high. Furthermore, only adult women taking oral contraception therapy were allowed to enter this trial, because abiraterone acetate will also inhibit gonadal steroid production. Consequently, the use of this drug might be limited to prepubertal children and patients taking gonadal replacement therapy who do not desire fertility. In theory, CYP17A1 inhibitors might be effective in nonclassic CAH as well; however, inhibition of cortisol synthesis complicates therapy. Selective 17,20-lyase inhibitors, which would not alter the glucocorticoid pathway, might be a superior alternative to complete CYP17A1 blockade, but these drugs would also impair gonadal function.
CORTICOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS
Another strategy to decrease the adrenal androgen excess is to directly prevent the hypophyseal ACTH production. This approach was recently explored with a selective CRH receptor type 1 antagonist, NBI-77860 [43 && ]. In a single-blind, placebo-controlled, fixed-sequence, single-dose trial, eight women with classic 21OHD were administered placebo or NBI-77860, 300 mg or 600 mg, at 22:00 h during three distinct treatment periods separated by 3-week washout intervals. NBI-77860 achieved dose-dependent reductions of ACTH and/or 17OHP in six of eight participants. Relative to placebo, NBI-77860 decreased ACTH and 17OHP by a mean of 43 and 0.7% for the 300 mg dose, respectively, and by 41 and 27% for the 600 mg dose, respectively. Variable reductions of androstenedione and testosterone were noted in this single dose study. A more sustained ACTH assuaging might be required to suppress these downstream steroids, and future longer-term studies to validate this hypothesis are needed.
CONCLUSION
Recent years have brought some long-awaited progress in the treatment of CAH, a relatively stagnant area for decades. Some of the advances made include: improved glucocorticoid delivery systems, both oral and parenteral, designed to better replicate the physiologic secretion and to diminish the exaggerated ACTH elevations; the development of nonglucocorticoid therapeutic alternatives, such as inhibitors of key androgen biosynthetic enzymes; and direct reduction of ACTH via CRH receptor antagonists. Each of these options has different advantages and pitfalls, as summarized in Table 1 . Larger trials to determine the long-term outcomes and safety profiles of these novel therapies in both adults and children should follow. Additional, yet unexplored, treatment options are theoretically plausible solutions (Fig. 2) , including ACTH receptor (melanocortin type 2 receptor) antagonists or second-generation androgen receptor antagonists (enzalutamide). It is important to emphasize that cortisol replacement therapy will always be required in patients with classic CAH, unless gene therapy or adrenal transplantation becomes feasible. Nevertheless, these new treatment approaches, alone or in combination, hold promise to bring additional benefits to CAH care.
